Mutations of MLC1 (KIAA0027), Encoding a Putative Membrane Protein, Cause Megalencephalic Leukoencephalopathy with Subcortical Cysts  by Leegwater, Peter A.J. et al.
Am. J. Hum. Genet. 68:831–838, 2001
831
Mutations of MLC1 (KIAA0027), Encoding a Putative Membrane Protein,
Cause Megalencephalic Leukoencephalopathy with Subcortical Cysts
Peter A. J. Leegwater,1,2 Bao Qiang Yuan,1 Jeffrey van der Steen,1,3 Joyce Mulders,1,3
Andrea A. M. Ko¨nst,2 P. K. Ilja Boor,1 Vlatka Mejaski-Bosnjak,4 Silve`re M. van der Maarel,5
Rune R. Frants,5 Cees B. M. Oudejans,2 Ruud B. H. Schutgens,2 Jan C. Pronk,1,3
and Marjo S. van der Knaap1
Departments of 1Child Neurology, 2Clinical Chemistry, and 3Human Genetics, Free University Medical Center, Amsterdam; 4Department of
Pediatrics, Children’s Hospital Zagreb, Croatia; and 5Department of Human Genetics, Leiden University Medical Center, Leiden,
The Netherlands
Megalencephalic leukoencephalopathy with subcortical cysts (MLC) is an autosomal recessive disorder characterized
by macrocephaly, deterioration of motor functions with ataxia, and spasticity, eventuating in mental decline. The
brain appears swollen on magnetic resonance imaging, with diffuse white-matter abnormalities and the invariable
presence of subcortical cysts. MLC was recently localized on chromosome 22qtel. We have narrowed down the
critical region by linkage analysis of 11 informative families with MLC to a region of ∼250 kb, containing four
known genes. One family with two patients who were siblings did not display linkage between the MLC phenotype
and any of the analyzed microsatellite markers on chromosome 22qtel, suggesting genetic heterogeneity and the
existence of at least a second MLC locus. The maximum two-point LOD score for the 11 families was 6.6 at
recombination fraction .02. Twelve different mutations in seven informative and six uninformative families were
found in one of the candidate genes,KIAA0027,which we renamed “MLC1.”The gene encodes a putativemembrane
protein with eight predicted transmembrane domains. The patients of one family were compound heterozygotes
for mutations that both introduced stop codons. The mutations further included frameshifts, splice-acceptor mu-
tations, a putative splice-donor mutation, and amino acid substitutions of residues in predicted transmembrane
domains. These data provide strong evidence that mutations of MLC1 cause the disease.
Introduction
Vacuolating megalencephalic leukoencephalopathy with
subcortical cysts (MLC [MIM 604004]) is a neurologic
disorder characterized by macrocephaly within the first
year and delayed onset of a slow deterioration of motor
functions with ataxia and spasticity (Van der Knaap et
al. 1995; Singhal et al. 1996; Topc¸u et al. 1998). The
cognitive functions are relatively spared. Magnetic res-
onance imaging of the brain is diagnostic and shows
diffusely abnormal, mildly swollen cerebral whitematter
and, invariably, subcortical cysts—in particular, in the
anterior-temporal region. A brain biopsy showed spon-
giform white-matter changes related to the presence of
numerous vacuoles between the outer lamellae of myelin
sheaths. The findings suggest either splitting of the outer
myelin lamellae along the intraperiod line or incomplete
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compaction (Van der Knaap et al. 1996). The mode of
inheritance is autosomal recessive. An MLC gene locus
has been recently assigned, by a genomewide linkage
analysis, to a 2-Mb interval on chromosome 22qtel
(Topc¸u et al. 2000). Although the study involved families
with MLC from a seemingly homogeneous Turkish pop-
ulation, a founder effect was not apparent from the pa-
tient haplotypes on chromosome 22qtel. In our study, the
critical region on chromosome 22qtel was narrowed
down by linkage analysis of a heterogeneous group of
MLC families with microsatellite markers. Recombi-
nation events in individual families that border the most
likely location of the disease gene were positioned more
precisely by the analysis of single-nucleotide polymor-
phisms (SNPs). Candidate genes that were located in the
critical region were screened by sequencing of patient
DNA, and we found mutations in one gene, KIAA0027,




All patients with MLC were diagnosed by one of us
(M.S.v.d.K.), and, with informed consent, blood samples
832 Am. J. Hum. Genet. 68:831–838, 2001
were collected. Sixteen patients with MLC were from
11 informative families of different ethnic origins. Six
of these families were of Turkish background. The other
five families were from Croatia, Japan, the United King-
dom (with Indian background), France, and Germany.
In nine families, the parents were consanguineous. The
informative families included five affected sib pairs and
12 healthy siblings. The estimated maximum LOD score
in these families was 13.4. We also studied 19 families
who were uninformative for linkage. These families,
with single patients and a total of 20 healthy siblings,
were of different white and Asian origins. Five of these
families were from Croatia.
Marker Analysis
Genomic DNA fragments were amplified as described
elsewhere (Leegwater et al. 1999). The markers
D22S1161 and D22S1169 were described by Dib et al.
(1996), and the oligonucleotide sequences for markers
D22S445 and UT580 were derived from The Genome
Database. The microsatellite markers ARSA and N66c4
were described by Topc¸u et al. (2000). The positioning
of these markers, except for D22S1161, was based on
the DNA sequence of chromosome 22 (Dunham et al.
1999). The positioning of D22S1161 was based on the
combination of the chromosome 22 DNA sequence and
genetic data (Dib et al. 1996). The DNA sequences of
the oligonucleotides for the marker 355c18 were 5′-
GTGTCCTGTGGGTATTCCAG-3′ and 5′-GAACCA-
GGGTGCAGTTCTTG-3′. These primers amplify a
polymorphic CA repeat around position 26300 of the
RP3 PAC clone 355c18. One of the primers for each of
the mentioned microsatellite markers had a fluorescent
label 6-FAM, HEX or TET at the 5′-end. The PCR
products of microsatellite DNA were analyzed with
an Applied Biosystems Genetic Analyzer 310. GS-500
TAMRA (Applied Biosystems) was used as a size stan-
dard and DNA from CEPH individual 1347-02 was an-
alyzed as a reference. The alleles correspond to the length
of the DNA fragments in base pairs. For the markers
UT580, 355c18, ARSA, and N66c4, the lengths were
derived from the GENESCANmeasurements. The prim-
ers for PCR amplification of the SNPs rs4469 and rs4624
were as described in the Web site A Database of Single
Nucleotide Polymorphisms. SNP rs8238 was amplified
with oligonucleotides 5′-ACCGTCTGCCTGCAGGG-
AT-3′ and 5′-GAACCCCATGTTCACACGTC-3′. The
DNA sequence of the SNP fragments was determined
by cycle sequencing with one of the PCR primers and
Big Dye terminators (Applied Biosystems), according to
the instructions of the manufacturer. The alleles corre-
spond to the base at the polymorphic position, as in A
Database of Single Nucleotide Polymorphisms.
Mutation Analysis
The DNA sequences of oligonucleotides for PCR am-
plification of the MLC1 exons and surrounding intron
sequences are available, on request, by e-mail. PCR
products ofMLC1 exons from patients of all MLC fam-
ilies were analyzed for SSCP, as described elsewhere
(Wijker et al. 1999). Exon fragments with banding pat-
terns that were different from control fragments were
further analyzed by cycle sequencing, as described
above. The PCR products of exon 2 from the hetero-
zygous patient M31 were subcloned in pGEMT vector
(Promega), as recommended by the supplier. The DNA
inserts of subclones were amplified by PCR and
sequenced.
Analysis of Brain MLC1 cDNA
Adult whole-brain cDNAwas obtained fromClontech
(Palo Alto). Overlapping fragments of MLC1 cDNA
were amplified by PCR, using standard conditions with
an annealing temperature of 55C. The primer combi-




TTA), and 114F-1362R. The primer numbers corre-
spond to the position on Genbank accession number
D25217. The PCR products were sequenced with the
PCR primers, as described.
Results
Using linkage analysis, we investigated the location of
the MLC gene on chromosome 22qtel in 11 informative
families with MLC. One family, ML10, did not display
linkage betweenMLC and chromosome 22qtel. This fam-
ily included two sibling patients who had different gen-
otypes for all seven microsatellite markers analyzed (fig.
1A). All other informative families displayed linkage be-
tween markers on chromosome 22qtel and MLC (data
not shown). The newly developed marker 355c18 was
the only microsatellite marker that showed overlap be-
tween the critical regions of the families with linkage
between MLC and chromosome 22qtel. The maximum
two-point LOD score for linkage between this marker
and MLC was 6.6 at recombination fraction .02. The
LOD score was calculated with the data for the 11 in-
formative families, and it proves that an MLC gene on
chromosome 22qtel is involved in these families. Analysis
of SNPs adjacent to 355c18 narrowed down the critical
region (fig. 1). The two sibling patients, M2 and M4,
of family ML1 in which the parents are first cousins, are
homozygous from D22S445 down to SNP rs8238. The
healthy sibling M6 was identical to these patients be-
tween D22S445 and UT580, but was a recombinant
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Figure 1 Localization of the MLC gene on chromosome22qtel. A, Chromosome 22qtel haplotypes of three informative families with MLC.
Microsatellite and SNP markers are listed on the left, according to their order. The alleles are depicted as PCR fragment length (microsatellites)
or DNA sequence at the polymorphic position (SNPs). Haplotypes that are identical by descent in individual patients are indicated by the boxes.
In family ML1, there are two patients with parents who are first cousins. The healthy sibling, M6, is a recombinant between markers UT580
and 355c18, indicated by the broken line. Patient M18 also has parents who are first cousins. Together, the two families limit the critical region
for MLC between rs4624 and rs8238. The two sibling patients in family ML10 do not share a genotype in the MLC region. B, Physical map
of the MLC region. The map is based on the completed and annotated DNA sequence of chromosome 22. Contig numbers and the position
of markers are indicated. The gaps between contigs are of unknown length. Vertical lines depict known ESTs and genes. The four candidate
EST clusters and genes are numbered: (1) KIAA0027 (“MLC1”); (2) dJ402G11.8 similar to MOV10; (3) dJ402G11.9 similar to MRS1; and
(4) dJ402G11.4.
between markers UT580 and 355c18 (fig. 1A). This fam-
ily, by itself, placed the most likely location of the MLC
gene in a 0.7-Mb interval between markers UT580 and
rs8238. Patient M18, whose parents are also first cous-
ins, was homozygous in the chromosomal region with
the four most distal markers starting with 355c18. The
frequency of the homozygous haplotype was estimated
between .02 and .005, indicating that the region was
identical by descent in patient M18. Together, families
ML1 and ML2 placed the most likely location of the
MLC gene on chromosome 22qtel, in a 250-kb region
between SNPs rs4624 and rs8238.
Four genes have been described in the annotated
DNA sequence of chromosome 22, between the SNPs
rs4624 and rs8238 (fig. 1B). We analyzed, by SSCP
analysis and DNA sequencing, two of the three coding
exons of dJ402G11.9 and all 11 coding exons ofMLC1,
of patients from all families with MLC. We found ev-
idence that MLC is caused by mutations inMLC1 (Gen-
bank accession number D25217) (fig. 2 and table 1).
The 12 different mutations in MLC1, found in 13
families with MLC, included formation of stop codons,
frameshifts, splice-site mutations, and amino acid sub-
stitutions of conserved residues and in predicted trans-
membrane domains (fig. 2 and table 1). The affected
sib-pair M31 and M32 was compound heterozygous
for mutations that both introduced stop codons in
MLC1 (fig. 2). One stop codon was created in exon 3
by mutation of a CrG residue at codon 71 of the open
reading frame (ORF). The mutation that led to a stop
codon in the second allele was a 4-bp deletion exactly
at the 3′ end of exon 7. The deletion was predicted, by
the program SPLICEVIEW (Rogozin and Milanesi
1997), not to affect the efficiency of the exon 7/intron
7 splice donor. The deletion directly led to a stop codon
at the exon 7/exon 8 junction. Patient M23, who comes
from the same country, was found to be heterozygous
for this allele (table 1). Patient M20 and the sib pair
M39 and M42 were homozygous for another micro-
deletion of 7 bp in exon 6 (fig. 2). The deleted 7 bp
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Figure 2 MLC1 mutations in genomic DNA of patients. Patient M31 was a compound heterozygote for a 4-bp deletion at the 3′ end of
exon 7 and a point mutation that led to a stop codon. The allele with the deletion was sequenced after subcloning of the PCR products. The
GT sequence of the splice donor is marked by an asterisk in this sequence. Lines indicate homologous residues of control and deletion mutant
DNA sequences. The electropherograms were obtained by automated DNA sequencing with PCR products from control and patient DNA
templates.
were part of an 8-bp direct repeat of the DNA sequence
TCCTGCTG, separated by a single C residue (fig. 2).
The repeats coded for leucine residues of the first of two
polyleucine motifs of the MLC1 protein product. Both
polyleucine motifs are part of predicted transmembrane
domains. Patient M120 was homozygous for a substi-
tution of 11 bp by 3 bp, resulting in a frameshift near
the 5′-end of exon 11 (fig. 2). This rearrangement oc-
curred in the region of seven TGC repeats, which en-
coded part of the second polyleucine motif. Interest-
ingly, the replacement sequence GCA was the reverse
complement of the repeat sequence. Patient M81 was
heterozygous for an insertion of 5 bp of the sequence
GGAGC, next to an inverted repeat with the same se-
quence in exon 6. The 5-bp insertion occurred at the
end of the domain that encoded the first polyleucine
motif.
The sibling patients M2 and M4 were homozygous
for a mutation of the splice-acceptor AG sequence of
exon 11 to GG. The next predicted splice acceptor was
51 nucleotides (nt) downstream from the mutated site.
Use of this site would result in a deletion of 17 amino
acids that constitute the major part of a predicted trans-
membrane domain. Similarly, patient M73 was hetero-
zygous for mutation of the AG of the splice-acceptor
site of exon 12 to GG. The next predicted splice ac-
ceptor was located downstream of the stop codon.
If this site were used, the 24 amino acids encoded by
exon 12 would be replaced by 27 unrelated residues.
Patient M14 was heterozygous for an insertion of a T
residue at position 3 of intron 5 (fig. 2). The insertion
probably caused incorrect splicing of this intron. The
SPLICEVIEW prediction diminished the score from
84% for the wild-type DNA sequence to 0% for the
insertion mutant (Rogozin and Milanesi 1997). The
next splice donor in the DNA sequence was located 94
bp downstream from the mutated junction. The intron
5 DNA sequence contained an in-frame stop codon and
the mutation in patient M14 probably led to a truncated
MLC1 gene product of 141 residues, with an addition
of 26 unrelated residues at the C-terminal end.
Four additional mutations were found in other pa-
tients with MLC that led to amino acid substitutions in
the MLC1 gene product (table 1). The serine residue at
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Table 1
MLC1 Mutations in DNA from MLC Patients
Patient Mutationa Effectb Exon State Origin Family Type
M62 954CrT S280L 10 Homozygous Japan Informativec
M66 393CrT S93L 4 Homozygous Japan Uninformative
M75 393CrT S93L 4 Homozygous Turkey Uninformative
M73 393CrT S93L 4 Heterozygous Japan Uninformatived
M73 IVS11-2ArG Aberrant splicing of exon 12 12 Heterozygous Japan Uninformativee
M2-M4 IVS10-2ArG Aberrant splicing of exon 11 11 Homozygous Turkey Informativec
M112 468CrG T118R 5 Homozygous Turkey Informativec
M14 IVS53insT Aberrant splicing of exon 5 5 Heterozygous India Uninformativee
M14 749GrA G212R 8 Heterozygous India Uninformatived
M20 564-570del L149 frameshift 6 Homozygous Turkey Informativec
M39-M42 564-570del L149 frameshift 6 Homozygous Middle East Informativec
M81 575insGGAGC E153 frameshift 6 Heterozygous Yugoslavia Uninformative
M23 709-712del Y198 stop 7 Heterozygous Croatia Uninformative
M31-M32 709-712del Y198 stop 7 Heterozygous Croatia Informatived
M31-M32 328CrG Y71 stop 3 Heterozygous Croatia Informativee
M120 1023-1033del3 V303 frameshift 11 Homozygous Turkey Informativef
a Numbers correspond to KIAA0027 cDNA (Genbank accession number D25217).
b Numbers correspond to translated KIAA0027, starting with the first methionine codon.
c Parents are first cousins.
d Maternal allele.
e Paternal allele.
f Parents are second cousins.
position 93, which was mutated in three patients from
Japan and Turkey (table 1), was conserved between
Xenopus and man (fig. 3A). This mutation was not
present in 100 chromosomes from unrelated Japanese
and 106 chromosomes from unrelated Turkish individ-
uals. The T118R mutation in patient M112, from Tur-
key, was not present in 106 chromosomes of Turkish
origin. This mutation shifted the predicted position of
the third transmembrane domain of the protein by 10
residues according to the TMpred program (Hofmann
and Stoffel 1993). Patient M62, from Japan, was ho-
mozygous for a mutation of the serine residue, at po-
sition 280, to a leucine residue. Again, this mutant allele
was not present in 100 chromosomes of Japanese origin.
Patient M14, of Indian background, was compound
heterozygous for the splice-donor mutation described
above and for mutation of the glycine residue at position
212 to an arginine residue (table 1). This mutation was
not present in 102 chromosomes from unrelated indi-
viduals from the same region. The four amino acid sub-
stitutions found in the MLC1 gene segregate with the
disease. The amino acids concerned are located in pre-
dicted transmembrane regions.
MLC1 is expressed in the brain and other tissues (No-
mura et al. 1994). We confirmed the identity of MLC1
transcripts by PCR amplification and DNA sequence
analysis of overlapping fragments from adult brain
cDNA. PCR amplification with three primer combi-
nations each resulted in single fragments that over-
lapped. The fragments were of expected size. The DNA
sequence was completely identical to the KIAA0027
clone, sequenced earlier (data not shown). These results
indicated that alternative splicing of MLC1 does not
occur in the brain.
Discussion
In this article, we describe the identification of the gene
for MLC. Of the 11 informative families studied, 10
displayed linkage between markers on chromosome
22qtel and MLC. It is possible that, in family ML10,
without apparent linkage, one of the sibling patients is
a double recombinant between markers UT580 and
355c18 or between 355c18 and ARSA, or that both
patients are recombinants between one of these marker
pairs, so that they may share a genotype in a small por-
tion of chromosome 22qtel. However, we have not yet
been able to detect a mutation in the patients, and the
most likely explanation for these results is the involve-
ment of another MLC locus in family ML10.
Recombination events that border the critical region
could be pinpointed by the use of SNP markers. Even-
tually, mutations in one of four candidate genes,MLC1,
proved to be responsible for the disorder. The four
amino acid substitutions investigated thus far are very
unlikely to be polymorphisms, since the mutations were
not represented in significant groups of control chro-
mosomes matched for ethnic background. Furthermore,
the substituted residues were conserved or located in
predicted transmembrane domains, suggesting that the
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Figure 3 Organization of MLC1. A, Conservation of the N-terminal end of the MLC1 gene product. The translated DNA sequences of
the Xenopus EST and MLC1 (Genbank accession numbers AW640978 and D25217, respectively) are compared. Vertical lines indicate identical
residues, and the plus sign () indicates conservative changes. The top line shows part of the 5′ end of the Xenopus EST with a stop codon
(underlined) in frame with the coding region. The stop codon that is 132 nt upstream of and in frame with the first methionine of MLC1 in
EST AU120203 is not shown. The asterisk (*) indicates the conserved serine residue that was mutated in patients M66, M73, and M75. B,
Genomic structure of MLC1. The exons are shown as boxes; introns, as solid lines. The gray parts indicate the eight regions that encode
transmembrane domains of the protein. The positions of the mutations that were found in DNA of patients with MLC are shown by arrows.
Interrupted lines indicate deviations from scale. M p start codon, X p stop codon, and fs p frameshift.
affected amino acids are important for MLC1 protein
function. One mutation probably led to deletion of a
transmembrane domain, and 8 of the 12 mutations led
to disruption and termination of the MLC1 ORF. In-
terestingly, the two DNA deletions and the duplication
involved direct and inverted repeats, respectively. The
deletion that occurred in patient M20 and the sib pair
M39 andM42 was probably the result of slipped-strand
mispairing in the region of the repeat prior to DNA
replication (Krawczak and Cooper 1991). Such a mech-
anism could not explain the rearrangement of the TGC
repeat region in patient M120. In this case, a deletion
of 8 bp was apparently accompanied by an inversion
of one repeat unit. The direct duplication of half an
inverted repeat in patient M81 may have been the result
of strand slippage by hairpin formation during DNA
replication.
We have not yet identified all disease-causing muta-
tions in our group of patients with MLC. Not all mu-
tations alter the mobility of DNA in SSCP analysis, and
large deletions in the heterozygous state can be missed,
because such alleles may fail to be amplified by PCR
(Morgan et al. 1999). Furthermore, we did not analyze
the promoter, the noncoding exon 1, complete introns,
and the 3′ UTR, all of which may influence the expres-
sion of the gene. Also, we cannot exclude that some of
the patients carry the gene for MLC at another locus.
The MLC1 cDNA was cloned from the immature
myeloid cell line KG-1, and the expression in these cells
proved to be high in comparison with the expression in
a variety of human tissues (Nomura et al. 1994). Of
the tissues examined, the expression of MLC1 was rel-
atively high in the brain. It was also expressed in pe-
ripheral white blood cells and spleen, and the expression
in ovary, prostate, placenta, thymus, and lung was rel-
atively low. No expression was observed in HeLa cells,
heart, liver, skeletal muscle, kidney, pancreas, testis,
small intestine, and colon. The northern blot forMLC1,
which can be viewed at the HUGE protein database,
shows a single band of the same size in these tissues.
We confirmed that MLC1 mRNA, with the same ORF,
is present in the brain, and we did not detect alternative
splice products. In the light of the expression pattern,
it is understandable that, if MLC1 exerts an essential
function, disruption of the gene would mainly affect the
brain. The fact that a gene for a neurological disorder
is not exclusively expressed in the nervous system is not
uncommon.
The ORF of the MLC1 cDNA has been described as
incomplete, because it started at the 5′-end and lacked
an apparent start codon (Nomura et al. 1994). How-
ever, a strong argument that theMLC1ORF is complete
can be found in the following facts. First, a recently
published expressed sequence tag (EST) (Genbank ac-
cession number AU120203) from the gene extended
exon 1 in the 5′ direction by 20 nt. This EST has a
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stop codon near the 5′ end in-frame with the MLC1
ORF and the first ATG codon in the extended cDNA
sequence corresponds with the first methionine codon
in the MLC1 ORF. Second, this methionine is appar-
ently evolutionarily conserved between man and Xen-
opus. A translated EST (Genbank accession number
AW640978) from unfertilized Xenopus egg cells is sim-
ilar to the N-terminal part of the MLC1 gene product,
starting with the first methionine residue. The methio-
nine codon of the Xenopus EST is in frame with an
upstream stop codon, indicating that this ATG is the
start codon of the Xenopus MLC1 gene (fig. 3A).
The genomic structure of MLC1 contains 12 exons
with the start codon in exon 2 and an untranslated 3′
end of 2.2 kb (fig. 3B). The TMpred program predicts
the MLC1 gene product to have eight transmembrane
domains. A BLAST search did not show homology of
the MLC1 product with proteins of known function,
although there was a low similarity to the human volt-
age-gated potassium channel KV1.1. A PROSITE pro-
file search indicated that the amino acid sequence con-
tained a signature motif of the ribosomal protein S14
subunit, but this match is listed by PROSITE as a false-
positive because the S14 ribosomal subunit gene obvi-
ously has been identified in higher eukaryotes. The
MLC1 amino acid sequence also matched the signature
of ABC-2 type transporters and of sodium:galactoside
symporters with low significance. Our working hy-
pothesis is thatMLC1 encodes a membrane protein that
may have a transport function for a specific, as yet un-
known, substrate.
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